

Report Date **2019-10-22**  
Published for **jwpark@crossangle.io**

Singapore  
CrossAngle Pte. Ltd.

Disclosure Level

**A+**

Xangle disclosure level policy

**A+** 57 or more

**A** 50 ~ 56

**B** 42 ~ 49

**C** 41 or less

(Out of total 63 questionnaires)

EN ▼

## Due Diligence Report



# Humanscape Technology Co., Limited

**HongKong**

(Country or jurisdiction of incorporation)

**2662562**

(Entity Registration Number)

**South Korea**

(Address, including zip code, including area code, of principal executive offices)

### Company Representative (Report Data Submitter)

Name	Position	Office Phone Number	Telegram ID
Haritson Choi	Blockchain Manager		c1hyuk

## TABLE OF CONTENTS

[I. Corporate Profile](#)

[II. Business Information](#)

[III. Financial Information](#)

[IV. Tokens](#)

[V. Listing](#)

## WHERE YOU CAN FIND MORE INFORMATION

Readers and others should note that the company announces material information to the public using the company website, press releases, public conference calls, and webcasts. They may also use the following social media channels as a means of disclosing information about the company, products, planned financial and other announcements and attendance at upcoming investor and industry conferences, and other matters.

Channels	Address
Company Website	<a href="https://humanscape.io">https://humanscape.io</a>
Twitter	<a href="https://twitter.com/Humanscape_ICO">https://twitter.com/Humanscape_ICO</a>
Company Blog	<a href="https://medium.com/humanscape-ico">https://medium.com/humanscape-ico</a>
Facebook	<a href="https://www.facebook.com/humanscape">https://www.facebook.com/humanscape</a>
Linkedin	<a href="https://www.linkedin.com/company/humanscape/">https://www.linkedin.com/company/humanscape/</a>
Github	<a href="https://github.com/humanscape">https://github.com/humanscape</a>
Reddit	<a href="https://www.reddit.com/r/Humanscape_official">https://www.reddit.com/r/Humanscape_official</a>
Telegram	<a href="https://t.me/Humanscape">https://t.me/Humanscape</a>
Custom Link	

The information posted through these social media channels may be deemed valid. Accordingly, the public should monitor these accounts and the blog, in addition to following company press releases, conference calls, and webcasts. This list may be updated from time to time and these channels may be updated without notice.

## PART I. Corporate Profile

### ITEM 1. Basic Corporate Profile

<b>Official Name of Company as specified in charter</b>	Humanscape Technology Co., Limited
<b>Establishment Date</b>	06 Aug 2018
<b>Jurisdiction of Incorporation</b>	HongKong
<b>Address of Principal Executive Offices</b>	South Korea
<b>Address of Official Company Registration</b>	FT C9, 20/F, MAI LUEN IND. BLDG, 23-31 KUNG YIP ST., KWAI CHUNG, NEW TERRITORIES, HONG KONG
<b>Entity Registration Number</b>	2662562
<b>Name of Company for Website Display</b>	Humanscape
<b>Description of Company</b>	Humanscape believes that systematically organized information from a good number of patients can be a solution to unconquered diseases. PGHD takes up around 60% of total amount of health data. However, due to the lack of a solid platform where it can be collected and organized in, it only exists in fragmented form. Humanscape, aim to free all mankind from diseases by integrating PGHD into one source.
<b>Number of employee</b>	26
<b>Company Website</b>	<a href="https://humanscape.io">https://humanscape.io</a>
<b>Whitepaper Link</b>	<a href="https://humanscape.io/whitepaper/Humanscape_Whitepaper_EN.pdf">https://humanscape.io/whitepaper/Humanscape_Whitepaper_EN.pdf</a>

### ITEM 2. Team

#### Executive Officers of the Registrant

The following sets forth certain information regarding the company's executive officers and founders, their details and positions as of 2019-10-22

Name	Position	Founder	Description
Stephen Chang	CEO	Yes	Majored in business administration at Sogang University. Once worked with a director to open an elderly nursing home, managing operational works from A to Z. Currently manages external business and introducing the project.

#### Engineering Team Leaders

The following sets forth certain information regarding the company's development and engineering leaders, their details and positions as of 2019-10-22

Name	Position	Team Name	Description
------	----------	-----------	-------------

Name	Position	Team Name	Description
Ted Lee	CTO	Humanscape Tech	<ul style="list-style-type: none"> <li>- Yonsei University, Seoul, Korea</li> <li>- Grand Finalist, Intel-DST Asia Pacific Challenge (Selected as the national representative team and participated as a member)</li> <li>- Software Maestro (Specialist training program), Ministry of Science, ICT and Future Planning</li> <li>- KAIST (Korea Advanced Institute of Science and Technology), Daejeon, Korea</li> <li>- Software Engineer &amp; Researcher, Kakao Corp</li> </ul>

## Advisory

The following sets forth certain information regarding the company's advisories, their details and positions as of 2019-10-22

Name	Company	Role of Advisor
No data available		

## Organization Structure

The following sets forth certain information regarding the structure of the company as of 2019-10-22

Name of Department/Group/Office/etc.	Number of Full-Time Staff	Number of Part-Time Staff	Head of Department (Maybe left blank)
Strategy	2	0	
Healthcare Business Development	2	2	
Tech	9	0	
Product	4	0	
Human&Culture	3	1	
Marketing	2	0	
CEO	1	0	
<b>Total</b>	<b>23</b>	<b>3</b>	

## PART II. Business Information

### ITEM 1. Business Overview

<b>Sector / Industry</b>	Information Technology / IT Services
<b>Category</b>	Health Care
<b>Business Model</b>	Humanscape is working to establish its namesake platform Humanscape, a decentralized patient network based on blockchains. Humanscape can provide practical help for patients to overcome their diseases through intellectual and emotional interaction with each other based on community activities. This process is expected to generate and collect a high volume of patient data, namely PGHD (Patient-Generated Health Data), on various disease groups. Furthermore, Humanscape facilitates active research into incurable diseases and the development of new drugs by linking patients to external industry sectors such as pharmaceutical firms and research institutes and helps patients to avoid complications and enjoy healthy lives through the continuous self-management of their lifestyle and symptoms. With these services, Humanscape is taking steps to liberate patients from incurable diseases, as its contribution to a world where everyone is healthy.

### ITEM 2. Industry Description

#### 2.1 Industry Overview

As existing blockbuster drugs are set to come off patent soon, it is hard for pharmaceuticals to avoid reduced profits caused by losing market share. Therefore, they have turned their eyes to new opportunities, such as gene therapy that is mainly focused on rare diseases. Considering the fact that more than 80% of rare diseases are genetic, it would be extremely beneficial for pharmaceuticals, both in time and cost-wise, to be able to collect patients' genetic data as pre-screening data in process of new drug development and clinical research. Realistically, however, it is a very difficult task.

#### 2.2 Target Market Size

+11.3% CAGR

: Worldwide orphan drug sales are forecast to grow at a CAGR of 11.3% from 2018 to 2024, double the rate forecast for the non-orphan drug market.

\$ 262bn

: By 2024, orphan drugs are expected to capture a fifth of worldwide prescription sales and to reach \$262bn.

1/3 pipeline

: Sales forecasts for pipeline orphan drugs account for over a third of total R&D pipeline sales.

#### 2.3 Recent Trends

##### (1) 23andMe Gets \$300 Million Boost From GlaxoSmithKline To Develop New Drugs

<https://www.forbes.com/sites/matthewherper/2018/07/25/23andme-gets-300-million-boost-from-glaxo-to-develop-new-drugs/#42e0cbbd3213>

##### (2) Roche To Buy Big Data Upstart Flatiron Health For \$1.9 Billion

<https://www.forbes.com/sites/matthewherper/2018/02/15/roche-to-buy-big-data-upstart-flatiron-health-for-1-9-billion/#79423cfd1e85>

##### (3) Psomagen and MacroGen Granted U.S. Patent for Blockchain Data-sharing Technology

<https://www.biospace.com/article/releases/psomagen-and-macrogen-granted-u-s-patent-for-blockchain-data-sharing-technology/>

## 2.4 Competitors

### 2.4.1 Existing Industry Competitors

The following sets forth certain information regarding the company's conventional competitors already established within the industry as of 2019-10-22:

Name	Country of Incorporation	Geographical Focus
Patientslikeme,	Cambridge, Massachusetts	

#### ***Patientslikeme,***

PatientsLikeMe's mission is to improve the lives of patients through new knowledge derived from shared real-world experience and outcomes.

### 2.4.2 Token Project Competitors

The following sets forth certain information regarding the company's competitors that have implemented Token economics as of 2019-10-22:

Name	Token Symbol	Blockchain Network
Nebula Genomics	NA	NA

#### **Nebula Genomics**

Nebula provides a private and secure way to learn what your genes say about your traits and ancestry. Nebula Explore is enabled by our next-generation DNA sequencing technology that generates a thousand times more data than technologies used by our competitors. We provide highly customized reports on new variants, risk scores, and research. Stay up-to-date on new research and how it affects you with the Nebula Library.

## ITEM 3. Project's Business Model

### 3.1 Business Description

#### **Target Customers**

- \* 350million Global Patient Numbers with Rare Diseases
- \* 7,000+ The Number of Rare Diseases

#### **Platform or Application Description**

MOAAH is a blockchain-based, data-oriented patient community especially for the ones with rare, incurable diseases that accompanies patients throughout the whole patient journey. Patients can refer to other patients' data with similar symptoms which are voluntarily shared by them. Pharmaceutical companies can also utilize all this data under the patients' consent and greatly shorten their new drug development and clinical research period, ultimately increasing chance of cure of rare, incurable diseases. MOAAH's beta version consists of three main features, <community, information and genetic test>.

#### **Business / Product / Services Overview**

##### **· Community**

For rare, incurable disease patients, there is only limited amount of information available in order to fully grasp their diseases and prepare the future. In MOAAH's community section, patients can share their know-hows on how to deal with their symptoms and also the wave of emotions they have to go through on daily basis. Posts and information will be shown by priority of their interest which are set according to their preferences.

##### **· Information**

Essential, useful and diverse information for patients, such as general disease information, current state of new drug development, government aid and insurance, tips for daily lives is listed and updated accordingly on information section. When it comes to medical information, it is not so easy for patients to look for, especially because it requires background knowledge or often is written in foreign language. In MOAAH, relevant information is well researched and curated by Humanscape team and patients can receive push alarm so they do not miss out on latest updates.

### · Genetic test

When it comes to rare, incurable diseases, 80% are congenital genetic disorders caused by genetic mutation. Therefore, it is crucial to have genetic test for precise diagnosis. In MOAAH's genetic test section, patients can easily apply for genetic test and often be subsidized by the project as well. Once they find their mutation, users will be provided with relevant medical information and clinical research news. Knowing the exact diagnosis and heritability will help to free patients from haze of anxiety.

## 3.2 Project development

### Vision & Mission

Together,  
we build healthier lives.

### History

It's been over four years since Humanscape has been a startup. We started at a cafe, then used a friend's studio as an office, and in early 2014 Humanscape started the company when we finally got an office through the Kang University Business Support Center.

Humanscape has been steadily carrying out projects in the healthcare field. Humanscape started with '허니비' calendar app for pregnant women. Then worked on identifying possible difficulties of patients and hospital staff through '거울아 거울아'. From combining the insight gained from working on these services, we launched a personal curating beauty care service called '뷰티케어'.

'뷰티케어' received a good response from our customer base. Therefore we expanded that platform by creating '헬렌' which was based on '뷰티케어'. We also launched '마크', a marketing solution for hospitals to identify possibilities to expand the business in hospital marketing. In this process, we attract investment from Mashup Angels and Magellan Technology Investment, which are both famous domestic investment companies.

Humanscape was able to acknowledge the possibility of collecting Patient Generated Health Data (PGHD) generated by patients through the projects that they had done before. However, because the projects done before were targeted at hospitals instead of directly targeting patients, we have found that rapid and widespread collection of PGHD was difficult. Fortunately, we found out that blockchain projects could give a chance to overcome these problems.

### Milestones

Title	Target Date	Status	Description
모아(MOAAH)서비스 리브랜딩, 업데이트	2019-12-27		희귀질환 환자들을 위한 모아(MOAAH)서비스 리브랜딩 및 업데이트를 진행할 계획입니다.
삼성 갤럭시 블록체인 월렛 등재	2019-07-08	Completed	미세톡톡이 삼성 갤럭시 s10, 노트10의 블록체인 월렛 dapp에 등재되었습니다.
미세톡톡 베타 오픈	2019-07-05	Completed	최초의 리워드 미세먼지 앱 미세톡톡의 베타 서비스를 오픈했습니다.
희귀난치 환자 커뮤니티 -모아(MOAAH) CBT 론칭	2018-06-27	Completed	희귀난치 환자군을 위한 커뮤니티 앱 서비스 모아(MOAAH)의 클로즈 베타 테스트를 시작했습니다.

## 3.3 Partnerships

The following sets forth certain information regarding the company's partners and partnership details as of 2019-10-22

### ▶ Seoul St.Mary's Smart hospital

#### Counterparty Details

Counterparty Website <https://www.cmcseoul.or.kr/page/main>

**Partnership Period****Revenue Generation** No**Partnership Details**

Humanscape and The Catholic Univ. of Korea Seoul St.Mary's smart hospital have signed joint research agreement on cancer patients. Through this research agreement, both parties will be conducting researches on prostate cancer.

**► MediBloc**

---

**Counterparty Details****Counterparty Website** <https://medibloc.org/ko/>**Partnership Period****Revenue Generation** No**Partnership Details**

Improvement of Patient-Generated Health Data through the partnership with MediBloc, obtaining patient records recorded inside the hospitals.  
Partnership of MediBloc and Humanscape will allow both to collect a full range of health data on patients from both inside and outside the hospi

**► Hanyang University Medical Center**

---

**Counterparty Details****Counterparty Website** <https://www.hyumc.com/eng/main.do>**Partnership Period****Revenue Generation** No**Partnership Details**

Humanscape signed an agreement with Hanyang University Medical Center a 'joint research agreement on patient data using a blockchain based patient network.' Through this agreement, both parties will be able to build useful infrastructure and make the best use of patients data collected on Humanscape platform for new drug and treatment.

**► Asan Medical Center(AMC)**

---

**Counterparty Details****Counterparty Website** <http://eng.amc.seoul.kr/gb/lang/main.do>**Partnership Period****Revenue Generation** No**Partnership Details**

Humanscape and Health Innovation Big Data Center of Asan Medical Center(AMC) have signed 'joint research agreement on using blockchain-based patient network'. This contract includes 'AMC medical expert staffs utilizing data from patients with rare, incurable diseases to develop new drugs and treatment'. This will certainly be a great help to strengthen the competitiveness needed for in-depth R&D.  
Through this contract, Humanscape will be functioning as a meaningful project for patients that proves the potential of well-structured patients-generated health data in real field.

### 3.4 Intellectual Property (Patents, Copyrights, Trade Secrets, and Trademarks)

No Input

### 3.5 Status of Legal Proceedings

No Input

## PART III. Financial Information

### ITEM 1. Equity Info.

The following sets forth company cap table of equity shareholders of the organization with more than 5% stake as of 2019-10-22  
Number of Shares Outstanding:

Shareholder Name	Title or Relations with Company	Percentage of Total Outstanding Shares	Number of Shares
MinHoo Chang	CEO	0	

### ITEM 2. Funding Info.

#### 2.1 Conventional Funding Rounds

Transaction Name	Announced Date	Number of Investors	Money Raised (In USD)	Lead Investors
No data available				

#### 2.2 Token Sale

##### Token Sale Funding

Funding achieved in relation to the target hard cap (%): 66.94

Proportion of ICO raised token supply allocated to individual investors from all ICO funding Rounds (%): 88

Amount of Tokens sold, incentives or discount terms offered to top 10 Token holders, and the lock-up period:

Bonus20%

Round Name	Start Date	End Date	Funding (In USD)*	Institutional Participants
Public 1	2018-05-31	2018-06-09	499,999.997	
Public 2	2018-06-20	2018-06-29	544,256.838	
Public 3	2018-07-31	2018-08-07	180,252.01	

\*: Proposed calculation, but not necessarily mandatory, is based on USD equivalent of cryptocurrency received between the start and end date of the Token sale duration calculated by  $((High+Low)/2)$  of market price

#### 2.3 Extraordinary Relations with Company

The following sets forth companies and organizations with extra-ordinary relations with company as of 2019-10-22

Company Name	Country of Incorporation	Start Date	End Date	Relationship Details
No data available				

### ITEM 3. Financial Disclosures

The following are simplified and condensed financial statements submitted by the company for disclosure last updated on 2019-10-22:

### 3.1 Simplified Income Statement

(USD)

---

Revenue

Cost of Goods Sold (COGS)

Gross Profit

Operating Expenses (SG&A)

Other Revenue & Expenses

---

Operating Income

### 3.2 Simplified Balance Sheet

(USD)

---

Fiat

Cash Equivalent

Total Fiat & Cash

DigitalAssets

---

Book Value of All Assets

### 3.3 Key Ratios

No data available

## PART IV. Tokens

### ITEM 1. Token Info.

**Token Symbol:** HUM

**Base Blockchain Platform:** Ethereum

**Type of Consensus:**

**Project Type:** Utility Token


**Project Status:**

**Total Token Supply:** 1,250,000,000

#### Token Description (Long):

HUM is the basic transactional token in Humanscape's blockchain. It can be purchased and sold in the exchange and transferred among users. The HUM holding is used for the operation of Humanscape .

#### Token Allocation Percentage:




### ITEM 2. Token Supply History

The following is a manual record Token supply history as of 2019-10-22. Corresponding transactions hashes have not been provided within this report.

Purpose	Date	Amount	Value (USD)	Post Total Supply	Post Circulating Supply
Hardfork(x1/100) for compliance	2019-08-14	1,084,734,273	N/A	1,084,734,273	N/A
Burning unsold Tokens in ICO	2019-01-29	16,526,572,662	N/A	108,473,427,338	N/A
Hardfork(x50) for security	2018-09-20	125,000,000,000	N/A	N/A	N/A
Token Release	2018-06-11	2,500,000,000	N/A	N/A	N/A

### ITEM 3. Token Ownership

The following is an automatic query result of wallet addresses based on balance holdings with meta data application as of 2019-10-22.



Rank	Address	Balance	Percentage
1	0xd0f4119ACF4078e7e99fC382260Cd4876AC426F5 (Unknown 1)	23,132,500,000.00	21.33%
2	0x0DAd852Bced6B530177c9d1B1b0C92719B627D6F (Unknown 2)	21,000,000,000.00	19.36%
3	0xe3031C1BfaA7825813c562CbDCC69d96FCad2087 (Unknown 3)	14,572,208,749.38	13.43%
4	0x60f13c93ddd2D82a8178dBCB7eeD8851aCFC8B9B (Unknown 4)	13,067,532,832.12	12.05%
5	0x65c675760c48269295666d0913C33B05eB11821d (Unknown 5)	6,250,000,000.00	5.76%
6	0x176819C94EFd4C5d61353872Ffb9451aaa0cF9eC (Unknown 6)	4,000,000,000.00	3.69%
7	0x32244010c70f177642D7Fb7913E88e74d5F7fd40 (Unknown 7)	2,356,720,000.00	2.17%
8	0x7bb1b7C8472B6a78b7292c8289C961FDa6C46a7F (Unknown 8)	1,766,193,501.80	1.63%
9	0xFD8b1e16De537584908c0F0178Ea032f9d41f190 (Unknown 9)	1,613,098,140.00	1.49%
10	0x626e5aec32aaa8b138760D315665e1A1465B77b3 (Unknown 10)	1,500,000,000.00	1.38%
11	0xB91b3442EDdf1A4f55B4957Fa7d7389C0e3d92A7 (Unknown 11)	1,200,000,000.00	1.11%
12	0xf52cC89c5e5e0c1EedF0271431877de802C9BC5E (Unknown 12)	1,100,000,000.00	1.01%
13	0xe0219d6109b3152D8a8d231470721f507Db9b2C0 (Unknown 13)	1,074,498,540.00	0.99%
14	0xA8d799a27f849F81c5F9dDcC1c51ecaBBB14A34 (Unknown 14)	1,050,000,000.00	0.97%
15	0x13c2382E7131622ee45c930430332F9553eC3E84 (Unknown 15)	1,000,000,000.00	0.92%
16	0x6B59210aDE46B62B25e82e95ab390A7CcAdd4c3a (Unknown 16)	973,660,216.25	0.90%
17	0xb187261EcBFa2d97947bb3ff4Cd153d4D1BeDa0b (Unknown 17)	900,000,000.00	0.83%


Rank	Address	Balance	Percentage
18	0x865bC78c75F15A4B723b213B64492bc0B8Ba6ad9 (Unknown 18)	650,000,000.00	0.60%
19	0x3f944fe673fcb1415233638D78748ad6e114F61f (Unknown 19)	582,176,443.00	0.54%
20	0xf25aEc6cAbd833feF770D9EfDA2d4f24B65F8367 (Unknown 20)	480,000,000.00	0.44%

## ITEM 4. Token Price and Market Cap

The following are market data present as of 2019-10-22.

Market Cap Rank **282**

### Price Performance



#### ▸ USD

**Current Price** : \$0.024945

**Change (7d/24h/1h)** : 75% | 41.2% | -0.8%

**Market Cap** : 11,230,981.79

**ICO Price** : \$0.020000

**Return since ICO** : 1.25 X

#### ▸ ETH

**Current Price** : 0.000143 ETH

**Change (7d/24h/1h)** : 85.5% | 41.3% | -0.7%


**Market Cap** : 64,332.20

**ICO Price** : 0.00000000 ETH

**Return since ICO** :


## ITEM 5. On-chain Performance

### Accumulated Wallet Count




Date	Accumulated Wallet Count	New Wallet Count
2019-08	31,659	81
2019-07	31,578	114
2019-06	31,464	301
2019-05	31,163	295
2019-04	30,868	840
2019-03	30,028	287
2019-02	29,741	183
2019-01	29,558	141
2018-12	29,417	343
2018-11	29,074	1,103
2018-10	27,971	4,997
2018-09	22,974	22,974

### Transfer Count



Date	Token Transfer Count
2019-08	283
2019-07	687
2019-06	975
2019-05	757
2019-04	2,267
2019-03	872
2019-02	627
2019-01	452
2018-12	1,166
2018-11	3,495
2018-10	18,976
2018-09	26,625

### Transfer Volume



Date	Token Transfer Volume
2019-08	9,467,520,473
2019-07	9,069,340,056
2019-06	10,548,214,853
2019-05	5,202,064,348
2019-04	23,508,433,608
2019-03	3,352,796,491
2019-02	121,486,657
2019-01	23,331,701,112
2018-12	3,272,088,586
2018-11	4,416,692,263
2018-10	35,620,331,818
2018-09	381,567,092,498

## PART V. Listing

### ITEM 1. Technical

#### Technical audit results and other equivalents

File	Date	Document Title	Audited by / Reported by
No data available			

#### Technical Compliance

**Q:** Can you ensure that your company has the technical capability to cooperate with exchanges? (Daemon/Wallet/Mainnet support/etc.) If your answer is yes, please use the input field to describe what necessary steps are required for the exchanges to engage in listing your project.

**A:** Yes

### ITEM 2. Legal

#### Legal Memorandums and Opinions

Date	Target Jurisdiction	Sender / Written by	File
No data available			

#### Legal Compliance

**Q:** Can you ensure that your project is in compliance with all laws in the countries that you conduct business and the jurisdiction of where your company is incorporated? Please use the input field to describe your circumstances in case you cannot ensure compliance.

**A:** Yes

**Q:** Can you ensure that there are no elements or features that potentially involve damaging public interests in certain countries due to the activities promoted by the project? (Gambling/drugs, etc.) Please use the input field to describe your circumstances in case you cannot ensure compliance.

**A:** Yes

**Q:** Can you ensure that your token/coin project is not categorized as a security under any existing global capital market regulations? Please use the input field to describe your circumstances in case you cannot ensure compliance.

**A:** Yes